Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: A novel synergistic therapeutic intervention

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 8, 2011, Pages 5441-5448

  Mitra, Moutushy ^a,b   Kandalam, Mallikarjuna ^a   Sundaram, Curam S ^c   Verma, Rama Shenkar ^d   Maheswari, Uma K ^b   Swaminathan, Sethuraman ^b   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b SASTRA UNIVERSITY   (India)

^c CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^d INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SMALL INTERFERING RNA; STATHMIN; VINCRISTINE; TUBULIN MODULATOR;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; RETINA TUMOR; TUMOR CELL CULTURE;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; MICROTUBULES; MITOTIC INDEX; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; RETINAL NEOPLASMS; RETINOBLASTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; STATHMIN; TRANSFECTION; TUBULIN MODULATORS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 80052811789     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6973     Document Type: Article

References (23)

1. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999;17:1061-1070.
2. Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. J Natl Cancer Inst. 2000;92:182-183.
3. Malawista SE, Sato H, Bensch KG. Vinblastine and griseofulvin reversibly disrupt the living mitotic spindle. Science. 1968;160:770-772.
4. Beck WT, Cass CE, Houghton PJ. Microtubule-targeting anticancer drugs derived from plants and microbes: vinca alkaloids, taxanes, and epothilones. In: Bast RC, Kufe DW, Pollack RE et al, eds. Cancer Medicine. 5th ed. London: B.C. Decker, Inc.; 2000:680-697.
5. DeVita V. Principles of cancer management: chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997:333-347.
6. Rodriguez-Galindo C, Chantada GL, Haik BG, Wilson MW. Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol. 2007;9:294-307.
7. Suárez F, Jockovich ME, Hernandez E, Feuer W, Parel JM, Murray TG. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma. Invest Ophthalmol Vis Sci. 2007;48:3437-3440.
8. Wang R, Dong K, Lin F, et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. Mol Med. 2007;13:567-575.
9. Mallikarjuna K, Sundaram CS, Sharma Y, et al. Comparative proteomics analysis of differentially expressed proteins in primary retinoblastoma tumors. Proteomics Clin Appl. 2010;4:449-463.
10. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimmers and increases the catastrophe rate of microtubules. Cell. 1996;84:623-631.
11. Laird AD, Shalloway D. Oncoprotein signaling and mitosis. Cell Signal. 1997;9:249-255.
12. Murphy ME, Cassimeris L. A novel cancer therapy approach targeting microtubule function. Cancer Biol Ther. 2006;5:1721-1723.
13. Mistry SJ, Atweh GF. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med. 2002;69:299-304.
14. Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol. 2007;71:1233-1240.
15. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002;62:6864-6869.
16. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell. 1996;84:623-631.
17. Gao P, Lin F. Inhibitory effects of stathmin gene SiRNA on cultured HeLa cell lines. J Modern Oncol. 2006;2:210-212.
18. Zhang HZ, Wang Y, Gao P, et al. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther. 2006;5:1457-1461.
19. Andersen SS. Spindle assembly and the art of regulating microtubule dynamics by MAPs and stathmin/Op18. Trends Cell Biol. 2000;10:261-267.
20. Holmfeldt P, Larsson N, Segerman B, et al. The catastrophepromoting activity of ectopic op18/stathmin is required for disruption of mitotic spindles but not interphase microtubules. Mol Biol Cell. 2001;12:73-83.
21. Howell B, Deacon H, Cassimeris L. Decreasing oncoprotein 18/ stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J Cell Sci. 1999;112:3713-3722.
22. Westendorf JM, Rao PN, Gerace L. Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci U S A. 1994;91:714-718.
23. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci U S A. 1983;80:2926-2930.